COVID-19 vaccine from Anhui earns conditional approval
By Wang Xiaoyu |
chinadaily.com.cn |
Updated: 2022-03-02 17:20
Share
Share - WeChat
China has given conditional approval for a recombinant protein subunit COVID-19 vaccine developed by domestic company Anhui Zhifei Longcom Biopharmaceutical, the National Medical Products Administration said on Wednesday.
The vaccine uses purified pieces of the virus' protein to trigger an immune response. It is the first vaccine based on this technology to be approved by the top drug regulator.
In total, five COVID-19 vaccines have been approved for public use in China so far.
- Gansu sets up team to probe abnormal blood lead levels in children
- China publishes Han-Tibetan version of major dictionary
- People advised to guard against dengue fever, diarrhea and other diseases
- Exploring China's Xixia Imperial Tombs with Yuanxi
- SCO foreign ministers council meeting to be held in Tianjin
- Foreign officials praise Chinese gardening culture for promoting harmony
